Chemotherapy-induced Peripheral Neuropathy - Market Insight, Epidemiology And Market Forecast - 2032

Key Highlights:

• Chemotherapy-Induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors.
• In 2022, the market size of chemotherapy-induced peripheral neuropathy was highest in the US, accounting for approximately USD 900 million, expected to increase by 2032.
• Chemotherapy-induced peripheral neuropathy presents clinically as sensory, motor, and sometimes autonomic function deficits. Sensory disturbances range from mild tingling to spontaneous burning pain and hypersensitivity to stimuli. These symptoms often affect both hands and feet and may spread into a 'glove/stocking' distribution. Symptoms are usually symmetrical distally but may be more severe unilaterally. Although dependent on the specific agent, the feet are often affected first.
• There is no sure way to prevent chemotherapy-induced peripheral neuropathy, but there are things one can do to manage their symptoms. Treatment can often help ease some of the symptoms of chemotherapy-induced peripheral neuropathy. Sometimes these symptoms go away a short time after treatment is done. But sometimes, they last much longer and need long-term treatment.
• Some drugs currently used in the treatment landscape are steroids, patches or creams, antidepressant medicines, anti-seizure medicines, and opioids or narcotics.
• The market is projected to grow by factors like an increase in the patient pool, projected entry of emerging therapy, i.e., Halneuron (Tetrodotoxin or TTX) and others, and their increasing usage in the treatment setting in the 7MM.

DelveInsight's 'Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the chemotherapy-induced peripheral neuropathy historical and forecasted epidemiology as well as the chemotherapy-induced peripheral neuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM chemotherapy-Induced peripheral neuropathy market size from 2019 to 2032. The report also covers current chemotherapy-induced peripheral neuropathy treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Chemotherapy-Induced Peripheral Neuropathy Disease Understanding and Treatment

Chemotherapy-Induced peripheral neuropathy overview

Anticancer medications like platinum, taxanes, epothilones, vinca alkaloids, and newer treatments like bortezomib frequently cause dose-dependent side effects. It results in dose reduction or therapy termination and lowers cancer survivors' quality of life; 20% of patients receiving conventional chemotherapy dosages and nearly 100% receiving high doses develop chemotherapy-induced peripheral neuropathy.

Clinical symptoms of chemotherapy-induced peripheral neuropathy include sensory, motor, and occasionally autonomic function impairments. Sensory disturbances can range from a slight tingling sensation to a scorching ache that appears out of nowhere and hypersensitivity to stimuli. These symptoms may expand into a "glove/stocking" distribution and frequently involve both hands and feet. Although they may be more severe unilaterally, symptoms are often symmetrical distally. Regardless of the exact agent, the feet are frequently the first to experience symptoms.

Chemotherapy-Induced Peripheral Neuropathy Diagnosis

Chemotherapy-induced peripheral neuropathy, a severe treatment-induced toxicity, can restrict function, degrade quality of life, and, in some circumstances, lessen the likelihood of a successful recovery when chemotherapy doses must be lowered. As more neurotoxic substances are developed, and individuals live longer with the effects of neuropathy, the prevalence of this disorder is rising.

Further details related to country-based variations are provided in the report…

Chemotherapy-Induced Peripheral Neuropathy Treatment

In patients actively receiving neurotoxic therapies, preventive treatments aim to lessen the frequency or severity of chemotherapy-induced peripheral neuropathy. These medications must retain the chemotherapeutic agent's antitumor effects in addition to lowering their neurotoxic effects if they are to be effective. Even if it is maintained in preclinical models and tests, the antitumor activity must still be confirmed in extensive clinical trials. Small case series demonstrating a reduction in chemotherapy-induced peripheral neuropathy with a certain medicine may not reveal the chemotherapy's possible, though the slight impact on the antitumor activity.

Due to a lack of high-quality, consistent evidence, the guidelines do not recommend any agents to prevent chemotherapy-induced peripheral neuropathy. However, the guidelines specify certain agents that should not be offered to prevent peripheral neuropathy in cancer patients undergoing treatment with neurotoxic agents.

Symptomatic treatments aim to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients who have already developed it after receiving neurotoxic drugs. Numerous symptomatic treatments have been researched, such as medications that alter neurotransmitter systems, ion channels, and terminal common pain pathways. Some of these treatments, such as antidepressants and anticonvulsants, may have peripheral or central effects on neurotransmitters or ion channels, which may modify how the central nervous system affects pain. Although these medications could be anticipated to treat all forms of neuropathy regardless of the underlying etiology, this is not the case.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Epidemiology

As the market is derived using a patient-based model, the Chemotherapy-Induced Peripheral Neuropathy (CIPN) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Chemotherapy-Induced Peripheral Neuropathy (CIPN), Severity-Specific Incident Population of Chemotherapy-Induced Peripheral Neuropathy (CIPN), Incident Population of Chemotherapy-Induced Peripheral Neuropathy (CIPN) by Chemotherapeutic Agents, and Incident Population of Chemotherapy-Induced Peripheral Neuropathy (CIPN) by Cancer Type in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

• The total incident population of chemotherapy-induced peripheral neuropathy in the 7MM was ~1,619,000 in 2022.
• Among the European countries, Germany had the highest incident population of chemotherapy-induced peripheral neuropathy with ~175,000 cases, followed by France, which had ~131,500 incident cases in 2022. On the other hand, Spain had the lowest incident population of chemotherapy-induced peripheral neuropathy, with ~79,000 cases in 2022. Japan had ~310,000 incident cases of chemotherapy-induced peripheral neuropathy in 2022.
• In terms of severity, most patients have been diagnosed with moderate severity. This was followed by mild severity; the least number was observed for severe cases.
• Most chemotherapy-induced peripheral neuropathy cases are caused by platinum-based chemotherapeutic agents followed by taxane agents. The fewest cases were observed with other chemotherapeutic agents (except platinum, taxane, and vinca alkaloid).

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Drug Chapters

The drug chapter segment of the chemotherapy-Induced Peripheral Neuropathy (CIPN) report encloses a detailed analysis of chemotherapy-induced peripheral neuropathy marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the chemotherapy-induced peripheral neuropathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Emerging Drugs

HALNEURON (TETRODOTOXIN or TTX): WEX Pharmaceuticals

HALNEURON (TETRODOTOXIN or TTX) is a small molecule targeting moderate-severe neuropathic pain without the side effects associated with opioid use. TTX blocks the voltage-gated sodium channels (VGSCs) found on nerves that conduct pain impulses, which are known to be affected in chronic pain conditions. Halneuron is an injectable formulation of tetrodotoxin, a novel small molecule with action on the peripheral nervous system. Halneuron does not cross the blood-brain barrier and therefore is without the common side effects of euphoria, addiction, tolerance, sedation, and confusion experienced by opioids and other analgesics. TTX is highly specific to VGSCs on the periphery without effects on the central nervous system. Halneuron is 3000 times more potent than morphine without opioid-like side effects. It is non-addictive, with no tolerance issues, and a long pain relief duration. WEX has completed 15 clinical trials with Halneuron, with more than 700 subjects being treated.

ATX01: AlgoTx

ATX01 is a first-in-class topical treatment for peripheral neuropathic pain. Its development focus is on the pain of chemotherapy-induced peripheral neuropathy and erythromelalgia. ATX01's pharmacological paradigm targets the epidermis and dermis - where the damaged nerve fibers sit - and avoids significant systemic absorption and its cascade of side effects. In June 2022, the US FDA granted Fast Track Designation to ATX01 for treating chemotherapy-induced peripheral neuropathy.

Note: Detailed emerging therapies assessment will be provided in the final report…

Drug Class Insights

Due to the lack of an approved therapy, no specific drug class has yet been well established in the treatment landscape of chemotherapy-induced peripheral neuropathy. The current therapeutic landscape of chemotherapy-induced peripheral neuropathy globally is dependent on off-label therapies like alpha-2-delta antagonists (anticonvulsants), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics, which are used to reduce the symptoms in patients.

Although HALNEURON has demonstrated the efficacy of voltage-gated sodium channel antagonists in clinical trials for chemotherapy-induced peripheral neuropathy, it blocks the voltage-gated sodium channels (VGSCs) found on nerves that conduct pain impulses, which are known to be affected in chronic pain conditions. It is an injectable formulation of tetrodotoxin, a novel small molecule with action on the peripheral nervous system. HALNEURON does not cross the blood-brain barrier and therefore is without the common side effects of euphoria, addiction, tolerance, sedation, and confusion experienced by opioids and other analgesics. It is highly specific to VGSCs on the periphery without affecting the central nervous system. HALNEURON is 3,000 times more potent than morphine without opioid-like side effects. It is non-addictive, with no tolerance issues, and a long pain relief duration.

Other mechanisms like Sigma 1 receptor antagonist (S1RA) and Protein C stimulants are also being explored in the different classes of drugs to treat chemotherapy-induced peripheral neuropathy.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook

The current therapeutic landscape of chemotherapy-induced peripheral neuropathy worldwide depends on off-label therapies used for symptom management, with no approved therapy in the treatment landscape to date. Despite the evaluation of many therapies traditionally used to treat neuropathic pain, no agent has demonstrated appropriate efficacy in preventing chemotherapy-induced peripheral neuropathy.

The most frequently administered drugs for the treatment of chemotherapy-induced peripheral neuropathy are opioid analgesics, Serotonin/norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressants (TCAs), Alpha-2-delta antagonists, and Topical analgesics. Of these drugs, opioids occupy the maximum market share in the US. The most commonly prescribed opioids include codeine, fentanyl, morphine, tapentadol, tramadol, and others. There have been obvious concerns about its addictive potential; however, these agents may be the best treatment option when used in properly selected patients. In Japan, the most frequently prescribed drugs for pain management were NSAIDs, followed by opioids or antiepileptic drugs. In Japan, apart from the above-mentioned drugs, a Japanese herbal product used for treating chemotherapy-induced peripheral neuropathy, the Kampo medicine (goshajinkigan), is composed of 10 natural ingredients and is classified as a drug that affects sensory nerves. Some studies suggested that goshajinkigan improved taxane-induced neuropathy.

Due to the lack of approved targeted therapies for treating chemotherapy-induced peripheral neuropathy, new targeted therapies are being developed by various companies across the globe. The overall dynamics of the chemotherapy-induced peripheral neuropathy market are prophesied to change during 2023-2032, owing to the expected launch of emerging therapies.

The key players that can significantly change the market during the forecast period include HALNEURON, ATX01, and thrombomodulin alfa. These drugs are in the clinical stages of development, which are evaluated in different stages of clinical development.

• The market size of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in the 7MM was ~USD 1,500 million in 2022.
• The market size of chemotherapy-induced peripheral neuropathy in the US was ~USD 900 million in 2022. Among EU4 and the UK, Germany had the highest market size for chemotherapy-induced peripheral neuropathy, i.e., ~USD 125 million, in 2022. The smallest market size was estimated in Spain, with ~USD 50 million in 2022.
• Due to the lack of approved targeted therapies, the current therapeutic landscape of chemotherapy-induced peripheral neuropathy in the US is mainly driven by off-label therapies. The major classes of off-label therapies which are prescribed to patients experiencing symptoms of chemotherapy-induced peripheral neuropathy include alpha-2-delta antagonists (anticonvulsants), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics, which act as good treatment options for neuropathic pain.
• HALNEURON/TETRODOTOXIN is a pipeline molecule expected to launch in the forecast period (2023-2032).

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2019-2032. For example, for HALNEURON/TETRODOTOXIN, which is expected to be launched in the US by 2028, the drug uptake is expected to be medium, with a probability-adjusted peak patient share of ~15% in the US, expected to peak at 6 years from the year of launch.

Further detailed analysis of emerging therapies drug uptake in the report…

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline development activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for chemotherapy-induced peripheral neuropathy emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts contacted for insights on the chemotherapy-induced peripheral neuropathy evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers and Professors from renowned universities in the US, Europe, the UK, and Japan.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Kyushu University Hospital, the University of Texas, etc., were contacted. Their opinion helped understand and validate current and emerging therapy treatment patterns of chemotherapy-induced peripheral neuropathy market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

The cost of newly approved medications is usually high, so patients escape from proper treatment or opt for off-label and cheap medications. It affects market access to newly launched medications, and reimbursement is crucial. The decision to reimburse often comes down to the 'drug's price relative to the benefit it produces in treated patients. Market access and reimbursement options can differ depending on regulatory status, target population size, the setting of care, unmet needs, the magnitude of incremental benefit claims, and costs.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of chemotherapy-induced peripheral neuropathy, explaining the definition of chemotherapy-induced peripheral neuropathy, types and risk factors involved in chemotherapy-induced peripheral neuropathy, pathophysiology, and the treatment of chemotherapy-induced peripheral neuropathy.
• Comprehensive insights into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the chemotherapy-induced peripheral neuropathy, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM chemotherapy-induced peripheral neuropathy market.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Report Insights

• Patient Population
• Therapeutic Approaches
• Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Analysis
• Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Size and Trends
• Existing and Future Market Opportunity

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Report Key Strengths

• Ten years Forecast
• The 7MM Coverage
• Chemotherapy-Induced Peripheral Neuropathy (CIPN) Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

Key Questions

Market Insights

• What was the chemotherapy-induced peripheral neuropathy total market size, the market size by therapies, and market share (%) distribution in 2019, and what would it look like by 2032? What are the contributing factors for this growth?
• What kind of uptake the new therapies approved will witness in chemotherapy-induced peripheral neuropathy patients in the coming years?
• Which therapy is going to be the largest contributor by 2032?
• What are the pricing variations among different geographies for approved therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of chemotherapy-induced peripheral neuropathy? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to chemotherapy-induced peripheral neuropathy?
• What is the historical and forecasted chemotherapy-induced peripheral neuropathy patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What is the diagnostic pattern of chemotherapy-induced peripheral neuropathy?
• Which clinical factors will affect chemotherapy-induced peripheral neuropathy?
• Which factors will affect the increase in the diagnosis of chemotherapy-induced peripheral neuropathy?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of chemotherapy-induced peripheral neuropathy? What are the current guidelines for treating chemotherapy-induced peripheral neuropathy in the US, Europe, the UK, and Japan?
• How many companies are developing therapies for the treatment of chemotherapy-induced peripheral neuropathy?
• How many emerging therapies are in the mid-stage and late stage of development for treating chemotherapy-induced peripheral neuropathy?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What key designations have been granted for the emerging therapies for chemotherapy-induced peripheral neuropathy?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?
• What is the 7MM historical and forecasted market of chemotherapy-induced peripheral neuropathy?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the chemotherapy-induced peripheral neuropathy market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis of emerging therapies to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.